Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
61 hedge funds and large institutions have $13.3M invested in Generation Bio in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 25 reducing their positions, and 33 closing their positions.
9.34% less ownership
Funds ownership: 71.19% → 61.86% (-9.3%)
23% less funds holding
Funds holding: 79 → 61 (-18)
31% less capital invested
Capital invested by funds: $19.3M → $13.3M (-$6.02M)
55% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 33
56% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$409K |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$333K |
| 3 |
Renaissance Technologies
New York
|
+$270K |
| 4 |
MCP
Militia Capital Partners
Las Vegas,
Nevada
|
+$209K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$60.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$927K |
| 2 |
BlackRock
New York
|
-$864K |
| 3 |
State Street
Boston,
Massachusetts
|
-$308K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$235K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$231K |
GBIO Hedge Fund Activity: Q2 2025 in Review
61 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2025, worth a combined $13.3M — down 31% from $19.3M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of GBIO and 15 opened new positions — a net loss of 18 holders — while 25 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $409K. The largest seller was Fidelity Investments, cutting an estimated $927K.
- 61 institutional investors held Generation Bio (GBIO) as of Q2 2025, down from 79 in Q1 2025.
- Funds reported $13.3M of Generation Bio stock for Q2 2025, down 31% quarter-over-quarter.
- 15 funds opened new Generation Bio positions in Q2 2025 and 33 closed out, a net change of -18 holders.
- The largest Generation Bio buyer in Q2 2025 was Millennium Management, an estimated $409K added.
- The largest Generation Bio seller in Q2 2025 was Fidelity Investments, an estimated $927K sold.
Based on aggregated 13F filings for Q2 2025.